Tarsus Pharmaceuticals

NasdaqGS:TARS Stock Report

Mkt Cap: US$456.4m

We’ve recently updated our valuation analysis.

Tarsus Pharmaceuticals Valuation

Is TARS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TARS?

Other financial metrics that can be useful for relative valuation.

TARS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13.3x
Enterprise Value/EBITDA-4.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TARS's PS Ratio compare to its peers?

TARS PS Ratio vs Peers
The above table shows the PS ratio for TARS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13.1x
FULC Fulcrum Therapeutics
29.1x45.3%US$421.0m
ESPR Esperion Therapeutics
6.6x48.9%US$445.9m
OCUL Ocular Therapeutix
6.4x38.5%US$319.4m
CARA Cara Therapeutics
10.3x36.5%US$502.9m
TARS Tarsus Pharmaceuticals
26.2x67.2%US$456.4m

Price-To-Sales vs Peers: TARS is expensive based on its Price-To-Sales Ratio (26.2x) compared to the peer average (13.1x).


Price to Earnings Ratio vs Industry

How does TARS's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: TARS is expensive based on its Price-To-Sales Ratio (26.2x) compared to the US Pharmaceuticals industry average (2.8x)


Price to Sales Ratio vs Fair Ratio

What is TARS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TARS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26.2x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: TARS is expensive based on its Price-To-Sales Ratio (26.2x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).


Share Price vs Fair Value

What is the Fair Price of TARS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TARS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TARS's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies